1
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNF.alpha.. BASF Aktiengesellschaft, Catherine J Kara, Elizabeth A Hanley Esq, Lahive & Cockfield, July 18, 2000: US06090382 (281 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.of ...


2

3
Min Wan, George Avgerinos, Gregory Zarbis Papastoitsis: Antibody purification. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin Howley Cowles, January 4, 2011: US07863426 (119 worldwide citation)

The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced ant ...


4
Jochen G Salfeld, Deborah J Allen, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, Hendricus R J M Hoogenboom, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin Howley Cowles, June 2, 2009: US07541031 (114 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


5
Jochen G Salfeld, Deborah J Allen, Hendricus R J M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A Mankovich, Brian T McGuinness, Andrew J Roberts, Paul Sakorafas, David Schoenhaut, Tristan J Vaughan, Michael White, Alison J Wilton: Human antibodies that bind human TNFα. Abbott Biotechnology, McCarter & English, Elizabeth A Hanley Esq, Cristin Howley Cowles, September 15, 2009: US07588761 (113 worldwide citation)

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTN ...


6

7
Mark L Nelson, Roger Frechette, Peter Viski, Beena Bhatia: 9-substituted minocycline compounds. Paratek Pharmaceuticals, Trustees of Tufts College, Lahive & Cockfield, Elizabeth A Hanley Esq, Cynthia M Soroos Esq, January 25, 2005: US06846939 (73 worldwide citation)

The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetra ...


8
Mark L Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tad Warchol, Paul Sheahan: 7, 9-substituted tetracycline compounds. Paratek Pharmaceuticals, Elizabeth A Hanley Esq, Cynthia M Soros, Lahive & Cockfield, January 27, 2004: US06683068 (73 worldwide citation)

The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compoun ...


9
Mark L Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith: 7-substituted tetracycline compounds. Paratek Pharmaceuticals, Trustees of Tufts College, Elizabeth A Hanley Esq, Cynthia M Soroos Esq, Lahive & Cockfield, November 16, 2004: US06818635 (72 worldwide citation)

The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tet ...


10
Mark L Nelson, Stuart B Levy, Roger Frechette, Todd E Bowser, Mohamed Y Ismail: 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds. Paratek Pharmaceuticals, Trustees of Tufts College, Elizabeth A Hanley Esq, Cynthia M Soroos Esq, Lahive & Cockfield, November 16, 2004: US06818634 (72 worldwide citation)

Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.